fda briefing moderna covid vaccine: overall, most frequently reported aes hypersensitivity smq were injection site rash 0.24% vaccine, 0.01% placebo , injection site urticaria 0.1% vaccine, 0% placebo , rash maculo-papular 0.07% vaccine, 0.01% placebo .